# Commercialization Analysis
Your Name

- [<span class="toc-section-number">1</span> Commercialization
  Analysis](#commercialization-analysis)
  - [<span class="toc-section-number">1.1</span> Setup](#setup)
  - [<span class="toc-section-number">1.2</span> Load
    Packages](#load-packages)
  - [<span class="toc-section-number">1.3</span> 1. Commercial
    Context](#1-commercial-context)
    - [<span class="toc-section-number">1.3.1</span> 1.1 Target Market
      (China)](#11-target-market-china)
    - [<span class="toc-section-number">1.3.2</span> 1.2 Competitive
      Landscape](#12-competitive-landscape)
  - [<span class="toc-section-number">1.4</span> 2. Business
    Model](#2-business-model)
    - [<span class="toc-section-number">1.4.1</span> 2.1 Value
      Proposition](#21-value-proposition)
    - [<span class="toc-section-number">1.4.2</span> 2.2 Revenue
      Streams](#22-revenue-streams)
  - [<span class="toc-section-number">1.5</span> 3. IP
    Strategy](#3-ip-strategy)
    - [<span class="toc-section-number">1.5.1</span> 3.1 Patent
      Portfolio](#31-patent-portfolio)
    - [<span class="toc-section-number">1.5.2</span> 3.2 Freedom to
      Operate (FTO)](#32-freedom-to-operate-fto)
  - [<span class="toc-section-number">1.6</span> 4. Regulatory
    Pathway](#4-regulatory-pathway)
    - [<span class="toc-section-number">1.6.1</span> 4.1 China Market
      Access](#41-china-market-access)
    - [<span class="toc-section-number">1.6.2</span> 4.2 International
      Expansion (Post-China)](#42-international-expansion-post-china)
  - [<span class="toc-section-number">1.7</span> 5. Manufacturing &
    Supply Chain](#5-manufacturing--supply-chain)
    - [<span class="toc-section-number">1.7.1</span> 5.1 Production
      Requirements](#51-production-requirements)
    - [<span class="toc-section-number">1.7.2</span> 5.2 Quality
      Control](#52-quality-control)
  - [<span class="toc-section-number">1.8</span> 6. Go-to-Market
    Strategy](#6-go-to-market-strategy)
    - [<span class="toc-section-number">1.8.1</span> 6.1 Customer
      Segments](#61-customer-segments)
    - [<span class="toc-section-number">1.8.2</span> 6.2 Pricing
      Strategy](#62-pricing-strategy)
  - [<span class="toc-section-number">1.9</span> 7. Financial
    Projections](#7-financial-projections)
    - [<span class="toc-section-number">1.9.1</span> 7.1 5-Year Revenue
      Projection](#71-5-year-revenue-projection)
    - [<span class="toc-section-number">1.9.2</span> 7.2 Funding
      Requirements](#72-funding-requirements)
  - [<span class="toc-section-number">1.10</span> 8. Risk
    Management](#8-risk-management)
    - [<span class="toc-section-number">1.10.1</span> 8.1 Risk
      Matrix](#81-risk-matrix)
    - [<span class="toc-section-number">1.10.2</span> 8.2 Exit
      Strategy](#82-exit-strategy)
  - [<span class="toc-section-number">1.11</span> 9. NotebookLM
    Validation](#9-notebooklm-validation)
    - [<span class="toc-section-number">1.11.1</span> 9.1 Query for
      Market Insights](#91-query-for-market-insights)
    - [<span class="toc-section-number">1.11.2</span> 9.2 Add Commercial
      Analysis to NotebookLM](#92-add-commercial-analysis-to-notebooklm)
  - [<span class="toc-section-number">1.12</span> 10. Session
    Info](#10-session-info)
  - [<span class="toc-section-number">1.13</span> 11. Final Milestones
    (12-Month Target)](#11-final-milestones-12-month-target)

# Commercialization Analysis

## Setup

<details class="code-fold">
<summary>Code</summary>

``` r
here::i_am(paste0(params$name, ".qmd"), uuid = "j0k1l2m3-n4o5-6789-pqrs-t1234567890")

qproj::proj_create_dir_target(params$name)
path_target <- qproj::proj_path_target(params$name)()
path_source <- qproj::proj_path_source(params$name)

# Read upstream data
path_09 <- qproj::proj_path_source("09-china-trial-analysis")
```

</details>

## Load Packages

<details class="code-fold">
<summary>Code</summary>

``` r
library(tidyverse)
library(here)
library(qproj)
library(ggplot2)
```

</details>

## 1. Commercial Context

### 1.1 Target Market (China)

From Notion Research Master Plan Section 13 (Market & Commercial
Context):

| Sector | Farmgate Value (¥ billions) | Antibiotic BAN Impact | Our Opportunity |
|----|----|----|----|
| **Poultry** | 1,200 | High (daily antibiotics banned) | Phage+Probiotic for broilers |
| **Aquaculture** | 800 | Medium (shrimp/fish) | Vibrio control + gut health |
| **Swine** | 1,500 | High (strict monitoring) | Salmonella control |
| **Cattle** | 600 | Low (mainly beef) | Limited focus |

**Primary target**: Poultry (fastest ROI, 禁抗令 impact最高)

### 1.2 Competitive Landscape

| Competitor | Product Type | Market Share | Strength | Weakness |
|----|----|----|----|----|
| **青岛诺安百特** (Qingdao Nuo’anbai) | Phage (mono) | Leading | Established sales network | No synergy approach |
| **CJ BIO** (Korea) | Probiotic (mono) | Strong | Large capacity | No phage integration |
| **Our Product** | **Phage+Probiotic Synergy** | New entrant | Scientific basis, bioinformatics-driven | Needs market entry |

## 2. Business Model

### 2.1 Value Proposition

**For farmers**: - Reduce mortality by X% (Module 09 results) - Improve
FCR by 0.1-0.15 points - No antibiotic residues (compliance with 禁抗令)

**For integrators**: - Traceable, sustainable production - Premium
pricing (“antibiotic-free” label) - Regulatory compliance

### 2.2 Revenue Streams

<details class="code-fold">
<summary>Code</summary>

``` r
revenue <- tibble(
  stream = c("Direct sales (phage)", "Direct sales (probiotic)", 
           "Combo product", "Licensing (IP)", "Consulting (trial design)"),
  margin_pct = c(60, 50, 70, 90, 80),
  scale_potential = c("High", "High", "High", "Medium", "Low")
)

knitr::kable(revenue, caption = "Revenue Streams Analysis")
```

</details>

| stream                    | margin_pct | scale_potential |
|:--------------------------|-----------:|:----------------|
| Direct sales (phage)      |         60 | High            |
| Direct sales (probiotic)  |         50 | High            |
| Combo product             |         70 | High            |
| Licensing (IP)            |         90 | Medium          |
| Consulting (trial design) |         80 | Low             |

Revenue Streams Analysis

## 3. IP Strategy

### 3.1 Patent Portfolio

From Notion Section 14 (IP & Patent Strategy):

| Patent | Coverage | Status | Timeline |
|----|----|----|----|
| **Phage cocktail composition** | Germany + PCT | Filed (Phase 2) | 3-5 years protection |
| **Synergy formulation** | China + PCT | Drafting | File Month 9 |
| **Application method** | China specific | Drafting | File Month 10 |
| **Probiotic strain selection** | Trade secret | Maintaining | Ongoing |

### 3.2 Freedom to Operate (FTO)

**Key risks**: 1. **青岛诺安百特**: May have broad phage patents →
design around 2. **CJ BIO**: Probiotic formulations → ensure strain
differentiation 3. **University patents**: Check academic licensing
options

**Mitigation**: - Use novel phage isolates (German strains → China
validation) - Combine with established GRAS probiotics (novel
combination = new IP) - File defensively (prevent competitors from
blocking)

## 4. Regulatory Pathway

### 4.1 China Market Access

| Step                  | Agency                  | Timeline           | Cost (¥) |
|-----------------------|-------------------------|--------------------|----------|
| **Lab validation**    | Internal                | Complete (Phase 2) | 50K      |
| **Pilot trial**       | Local FAIRS             | Month 7-9          | 200K     |
| **Full trial**        | Ministry of Agriculture | Month 10-15        | 500K     |
| **Production permit** | Provincial gov          | Month 16-18        | 100K     |
| **Sales license**     | National                | Month 19-20        | 50K      |

**Total timeline**: ~20 months from lab validation to market.

### 4.2 International Expansion (Post-China)

| Market  | Regulation | Timeline   | Entry Strategy          |
|---------|------------|------------|-------------------------|
| **EU**  | EFSA       | 24+ months | Partner with EU firm    |
| **USA** | FDA        | 18+ months | CJ BIO partnership?     |
| **SEA** | Variable   | 12 months  | China model replication |

## 5. Manufacturing & Supply Chain

### 5.1 Production Requirements

**Phage production**: - Scale: 10^12 PFU/month (serves 1M birds) -
Facility: BSL-2 lab (China partner) - Cost: ¥0.05/dose (target)

**Probiotic production**: - Scale: 1 ton/month (lyophilized) - Facility:
GMP certified (existing partner) - Cost: ¥0.03/dose (target)

### 5.2 Quality Control

| Test                    | Frequency   | Method              | Standard            |
|-------------------------|-------------|---------------------|---------------------|
| **Phage titer**         | Every batch | Double agar layer   | \>10^9 PFU/mL       |
| **Probiotic viability** | Every batch | Plate count         | \>10^9 CFU/g        |
| **Sterility**           | Every batch | Membrane filtration | No growth           |
| **Heavy metals**        | Quarterly   | ICP-MS              | Meet feed standards |

## 6. Go-to-Market Strategy

### 6.1 Customer Segments

| Segment | Size | Priority | Approach |
|----|----|----|----|
| **Large integrators** (Wens, New Hope) | 5-10 firms | P0 (Highest) | Direct sales team |
| **Medium farms** (10K-100K birds) | 1,000+ | P1 | Distributor network |
| **Feed mills** | 50+ | P2 | B2B ingredient sales |
| **Aquaculture** | 200+ farms | P3 | Specialized channel |

### 6.2 Pricing Strategy

**Cost-plus pricing**: - Production cost: ¥0.08/bird (phage +
probiotic) - Target price: ¥0.15/bird (47% margin) - Premium tier:
¥0.20/bird (if FCR improvement \>0.15)

**Competitive pricing**: - 诺安百特 phage only: ¥0.18/bird - Our
synergy: ¥0.15/bird (better efficacy, lower price)

## 7. Financial Projections

### 7.1 5-Year Revenue Projection

<details class="code-fold">
<summary>Code</summary>

``` r
years <- 1:5
revenue_m <- c(0.5, 5, 20, 50, 100)  # Million ¥
cost_m <- c(2, 4, 10, 20, 40)  # Million ¥
profit_m <- revenue_m - cost_m

projections <- tibble(
  Year = years,
  Revenue_M = revenue_m,
  Cost_M = cost_m,
  Profit_M = profit_m,
  Cumulative_Profit = cumsum(profit_m)
)

knitr::kable(projections, caption = "5-Year Financial Projection (Million ¥)")
```

</details>

| Year | Revenue_M | Cost_M | Profit_M | Cumulative_Profit |
|-----:|----------:|-------:|---------:|------------------:|
|    1 |       0.5 |      2 |     -1.5 |              -1.5 |
|    2 |       5.0 |      4 |      1.0 |              -0.5 |
|    3 |      20.0 |     10 |     10.0 |               9.5 |
|    4 |      50.0 |     20 |     30.0 |              39.5 |
|    5 |     100.0 |     40 |     60.0 |              99.5 |

5-Year Financial Projection (Million ¥)

<details class="code-fold">
<summary>Code</summary>

``` r
ggplot(projections, aes(x = Year)) +
  geom_line(aes(y = Revenue_M, color = "Revenue")) +
  geom_line(aes(y = Cost_M, color = "Cost")) +
  geom_line(aes(y = Cumulative_Profit, color = "Cumulative Profit")) +
  theme_minimal() +
  labs(title = "Financial Projection (Million ¥)",
       y = "Million ¥",
       color = "Legend")
```

</details>

![](10-commercialization-analysis_files/figure-commonmark/projections-1.png)

**Break-even**: Month 30 (2.5 years)

### 7.2 Funding Requirements

| Round | Amount (M¥) | Use | Source |
|----|----|----|----|
| **Seed** (Month 0-6) | 2M | R&D, pilot trial | Government grant (DFG-equivalent), angel |
| **Series A** (Month 12) | 10M | China trial, production setup | VC (agtech focus) |
| **Series B** (Month 24) | 50M | Market expansion | VC, strategic investor |

## 8. Risk Management

### 8.1 Risk Matrix

| Risk | Probability | Impact | Mitigation |
|----|----|----|----|
| **Regulatory delay** | Medium | High | Start approvals early (Month 1) |
| **Competitor blocking** | Low | High | Strong IP portfolio, design around |
| **Phage resistance** | High | Medium | Use cocktails (3+ phages) |
| **Market rejection** | Low | High | Pilot trials with key customers |
| **Production failure** | Low | Medium | Partner with established facility |

### 8.2 Exit Strategy

**Options** (Month 60+): 1. **Acquisition** by 诺安百特 / CJ BIO
(valuation: 500M-1B ¥) 2. **IPO** on ChiNext/SSE (minimum 3 years
profit) 3. **Licensing** to multinational (royalty stream)

## 9. NotebookLM Validation

### 9.1 Query for Market Insights

``` bash
nlm notebook query phage-synergy "What is the market size for phage therapy in China animal agriculture?"
```

### 9.2 Add Commercial Analysis to NotebookLM

After finalizing commercial plan:

``` bash
nlm source add phage-synergy --text "$(cat commercial_analysis.txt)" \
  --title "Commercialization Analysis pr0117"
```

## 10. Session Info

<details class="code-fold">
<summary>Code</summary>

``` r
sessionInfo()
```

</details>

    R version 4.5.3 (2026-03-11)
    Platform: aarch64-apple-darwin20
    Running under: macOS Tahoe 26.3.1

    Matrix products: default
    BLAS:   /Library/Frameworks/R.framework/Versions/4.5-arm64/Resources/lib/libRblas.0.dylib 
    LAPACK: /Library/Frameworks/R.framework/Versions/4.5-arm64/Resources/lib/libRlapack.dylib;  LAPACK version 3.12.1

    locale:
    [1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

    time zone: Europe/Berlin
    tzcode source: internal

    attached base packages:
    [1] stats     graphics  grDevices utils     datasets  methods   base     

    other attached packages:
     [1] qproj_0.1.5     here_1.0.2      lubridate_1.9.5 forcats_1.0.1  
     [5] stringr_1.6.0   dplyr_1.2.1     purrr_1.2.1     readr_2.2.0    
     [9] tidyr_1.3.2     tibble_3.3.1    ggplot2_4.0.2   tidyverse_2.0.0

    loaded via a namespace (and not attached):
     [1] gtable_0.3.6       jsonlite_2.0.0     compiler_4.5.3     tidyselect_1.2.1  
     [5] scales_1.4.0       yaml_2.3.12        fastmap_1.2.0      R6_2.6.1          
     [9] labeling_0.4.3     generics_0.1.4     knitr_1.51         rprojroot_2.1.1   
    [13] tzdb_0.5.0         pillar_1.11.1      RColorBrewer_1.1-3 rlang_1.2.0       
    [17] stringi_1.8.7      xfun_0.57          fs_2.0.1           S7_0.2.1          
    [21] otel_0.2.0         timechange_0.4.0   cli_3.6.5          withr_3.0.2       
    [25] magrittr_2.0.5     digest_0.6.39      grid_4.5.3         hms_1.1.4         
    [29] lifecycle_1.0.5    vctrs_0.7.2        evaluate_1.0.5     glue_1.8.0        
    [33] farver_2.1.2       codetools_0.2-20   rmarkdown_2.31     tools_4.5.3       
    [37] pkgconfig_2.0.3    htmltools_0.5.9   

## 11. Final Milestones (12-Month Target)

✅ **Month 0-2**: Bioinformatics analysis (Phase 1) — **COMPLETE** ✅
**Month 0-3**: Mechanism exploration + proxy strains (Phase 2) —
**COMPLETE** 🔄 **Month 0-6**: Experimental design + manuscript (Phase
3) — **IN PROGRESS** 🔄 **Month 0-12**: China trials + commercialization
(Phase 4) — **PLANNED**

**Deliverables by Month 12**: 1. ✅ Grant application (preliminary data
ready) 2. 🔄 Manuscript submitted (Phase 3) 3. 🔄 China trial completed
(Phase 4) 4. 🔄 Series A funding (¥10M) 5. 🔄 Market entry (sales
license)

------------------------------------------------------------------------

*Generated by qproj workflow for pr0117-PhageProbioticSynergy*
